Early TNM stage (p < 0.001) (in the entire cohort – Figure 3B; in all patients with tumors with mutation(s) – Figure 3C; without mutations – Figure 3D; in all patients with EGFR-mutant and ALK-rearranged tumors – Figure 3E), adenocarcinoma histology (p = 0.012), good performance status (PS) (Eastern Cooperative Oncology Group, ECOG 0 vs. 1 vs. 2/3) at diagnosis (p < 0.001) and treatment with targeted therapy (p < 0.001) were each associated with longer OS. The gene discussed is ALK; the disease is adenocarcinoma.